Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2392019A
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2392019A is a recombinant protein subunit vaccine developed by GSK for the prevention of *Staphylococcus aureus* infections, particularly surgical site infections in patients undergoing elective spinal surgery. The vaccine is a four-component formulation (4C-Staph) comprising the antigens alpha-hemolysin (HlaH35L), the EsxA-EsxB fusion protein, ferric hydroxamate-binding lipoprotein (FhuD2), and the conserved surface protein Sta011. It is formulated with GSK's proprietary AS01 adjuvant system (specifically AS01B or AS01E) to enhance the immune response. Despite progressing to Phase 2 clinical trials, GSK discontinued the development of the vaccine after it failed to demonstrate sufficient efficacy in preventing *S. aureus* infections in the target surgical population.
- Other names
- 4C-Staph4-component Staphylococcus aureus vaccineStaphylococcus aureus vaccine (4-component, adjuvanted)
02
Targets
FhuD (Staphylococcus aureus ferric hydroxamate-binding lipoprotein)Hla (Staphylococcus aureus alpha toxin)Sta011 (Staphylococcus aureus surface protein Sta011)EsxA-EsxB (Staphylococcus aureus EsxA-EsxB complex)
Beyond the preview
Go deeper on GSK2392019A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2392019A.